Elsevier

Neuropharmacology

Volume 39, Issue 1, January 2000, Pages 1-10
Neuropharmacology

Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels

https://doi.org/10.1016/S0028-3908(99)00153-7Get rights and content

Abstract

The voltage gated calcium channel family is a major target for a range of therapeutic drugs. Mibefradil (Ro 40–5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block T-type Ca2+ channels. However, this molecule has also been shown to inhibit other Ca2+ channel subtypes. To further analyze the mechanism governing the Ca2+ channel–Mibefradil interaction, we examined the effect of Mibefradil on various recombinant Ca2+ channels expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration. Expression of α1A, α1C and α1E in tsA 201 cells resulted in Ca2+ currents with functional characteristics closely related to those of their native counterparts. Mibefradil blocked α1A and α1E with a Kd comparable to that reported for T-type channels, but had a lower affinity (∼30-fold) for α1C. For each channel, inhibition by Mibefradil was consistent with high-affinity binding to the inactivated state. Modulation of the voltage-dependent inactivation properties by the nature of the coexpressed β subunit or the α1 splice variant altered block at the Mibefradil receptor site. Therefore, we conclude that the tissue and sub-cellular localization of calcium channel subunits as well as their specific associations are essential parameters to understand the in vivo effects of Mibefradil.

Introduction

Voltage-gated calcium channels (VGCCs), are transmembrane proteins involved in the regulation of cellular excitability and Ca2+ homeostasis. VGCCs, classified as L-, N-, P-, Q-, R- and T-type based on their functional properties, are critical for many cellular functions including muscular contraction, neurotransmitter release and excitability. To date, ten Ca2+ channels genes have been reported and termed α1S for the first one identified in skeletal muscle and α1A through to α1I for the nine others isolated subsequently (Perez-Reyes et al., 1998). When transiently expressed from their cDNA in a host system together with their ancillary β and α2δ subunits, α1A exhibits the characteristics of P- and Q-type channels, α1B encodes an N-type channel, α1C α1D and α1S constitute three different types of L-type channels, and α1E seems to correlate to resistant R-type channels defined as VGCCs insensitive to all known Ca channel antagonists and toxins. The recently described α1F gene is highly homologous to α1D and probably corresponds to an L-type channel (Fisher et al., 1997). Finally, α1G α1H and α1I the latest genes identified, have been unambiguously characterized as members of the T-type Ca channel family (Perez-Reyes et al., 1998, Cribbs et al., 1998, Lee et al., 1999).

VGCCs are major targets for a variety of therapeutic agents such as dihydropyridines (DHPs), benzothiazepines (BTZs), and phenylalkylamines (PPAs) that are used in the treatment of hypertension, stroke, acute ischemia, migraine and epilepsy. These drugs are considered as L-type Ca2+ channel antagonists. In addition to the DHPs, BTZs and PAAs, a new molecule (Mibefradil, a tetralole derivative) has been described with a potent action on low-voltage activated T-type VGCCs (Mishra and Hermsmeyer, 1994). Mibefradil has proven to be effective in the treatment of cardiovascular diseases but the relationship between the clinical effect (hypotension with no increase in heart rate) and the inhibition of T-type channels has not clearly been established. In addition to the block of T-type Ca2+ channels, Mibefradil was also reported to block channels induced by α1A, α1B, α1C and α1E expression in Xenopus oocytes (Bezprozvanny and Tsien, 1995). To further compare Mibefradil blockade of different calcium channel subtypes, we studied its action on three major classes of cloned Ca2+ channels. Our results provide the first comparison of the effect of Mibefradil on recombinant α1A, α1C, α1E currents in nearly physiological conditions (transiently expressed in mammalian cells and currents recorded in physiological levels of external calcium). In addition, our results show that the voltage-dependent kinetics of inactivation of Ca2+ channels, determined by the nature of the associated β subunit isoform and/or alternative splicing of the α1 gene, is critical for the action of Mibefradil.

Section snippets

Transient expression of recombinant calcium channels

cDNAs encoding VGCCs α1, α2 and β subunits and reporter genes (CD8 or GFP) were inserted in vertebrate expression vectors. Rat brain α1A isoforms, α1E, β2a, and α2δ were cloned in pMT2 (Stea et al., 1994, Soong et al., 1993, Bourinet et al., 1999); rat brain α1C and β1b, in pCEP4 (Tomlinson et al., 1993); and CD8 (generously provided by Dr Brian Seed, Massachusetts General Hospital) and GFP (a kind gift from Dr Kye Chesnut, University of Florida) in CMV promoter driven vectors. Human embryonic

Recombinant Ca2+ currents in mammalian cells

Transfection of rat α1A, α1C, or α1E with α2-δ and β1b subunits produced a robust expression of Ca2+ channels as determined by the presence of a large Ca2+ current density. This allowed the comparison of these three major types of VGCCs with a physiological concentration of Ca2+ as the charge carrier. The α1A α1C and α1E channels were activated by depolarization greater than −40 to −30 mV, had a maximum amplitude around 0 mV, and reversed near +60 mV (Fig. 1). They all deactivated with

Discussion

The repertoire of therapeutic molecules acting on VGCCs (also called Ca2+ channel antagonists) is to date restricted to L type channels, and therefore preferentially targets cell types expressing these channels (mostly cardiovascular cells). In contrast a recently developed molecule, Mibefradil, has been reported to be more selective for T-type vs L-type Ca2+ channels in cardiovascular tissues (Mishra and Hermsmeyer, 1994, Benardeau and Ertel, 1998). Therefore T-type Ca2+ channel blockade

Concluding remarks

Altogether, our data are consistent with a voltage-dependent block which implies that Ca2+ channel diversity resulting from combinations of the different types of α1 subunits (and their respective variants) and the different β subunits may significantly affect pharmacological properties. Demonstration of a potent block by Mibefradil of various HVA calcium channels in the same range of concentration as that blocking T-type channels should contribute to our understanding of the drug effects, and

Acknowledgements

We are grateful to Ed Perez Reyes for providing the β2a cDNA and to Robert Koen for the Mibefradil. We thank Gerald Zamponi, Mike Seagar and Matteo Mangoni for careful reading of the manuscript. This work was supported by NATO grant CGR971546 (E.B.), by Ministerio de Educación y Cultura Español fellowship (C.J.), by AFM grant (J.N.), and by Produits Roche, Neuilly, France.

References (34)

  • I. Bezprozvanny et al.

    Functional impact of syntaxin on gating of N-type and Q-type calcium channels

    Nature

    (1995)
  • B.P. Bean

    Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state

    Proceedings of the National Academy of Sciences USA

    (1984)
  • A. Benardeau et al.

    Selective block of myocardial T-type calcium channel by Mibefradil: a comparison with the 1,4-dihydropyridine Amlodipine

  • E. Bourinet et al.

    The α1E calcium channel exhibits permeation properties similar to low-voltage-activated calcium channels

    Journal of Neuroscience

    (1996)
  • E. Bourinet et al.

    Splicing of α1A subunit gene generates phenotypic variants of P- and Q-type calcium channels

    Nature Neuroscience

    (1999)
  • T. Collin et al.

    Cloning, chromosomal location and functional expression of the human voltage-dependent calcium-channel beta 3 subunit

    European Journal of Biochemistry

    (1994)
  • L.L. Cribbs et al.

    Cloning and characterization of α1H from human heart, a member of the T-type Ca2+ channel gene family

    Circulatory Research

    (1998)
  • Cited by (62)

    • The Hard-To-Close Window of T-Type Calcium Channels

      2019, Trends in Molecular Medicine
      Citation Excerpt :

      Analogs of mibefradil have been synthetized by replacing a methoxyacetyl ester with more lipophilic groups to limit cytoplasmic hydrolysis, and NNC-55-0396 was distinguished by its potent and selective TTCC-blocking properties [24,55]. Both mibefradil and NNC-55-0396 exert poorly reversible blockade consistent with high-affinity binding to the inactivated state, and it is suggested that the drug-binding sites reside within transmembrane domains [56–60]. Slow onset seems to be responsible for notable discrepancies among reported blocking potencies [55].

    • Differential CaMKII regulation by voltage-gated calcium channels in the striatum

      2015, Molecular and Cellular Neuroscience
      Citation Excerpt :

      However, basal CaMKIIα autophosphorylation was partially blocked by mibefradil, a selective TTCC blocker. Mibefradil has been reported to also block LTCCs at somewhat higher concentrations (Martin et al., 2000; Jiménez et al., 2000), but the lack of effect of dihydropyridines (see above) strongly suggests that LTCCs are not involved under basal conditions. Moreover, CaMKIIα autophosphorylation was also decreased by incubating slices with NiCl2, which at the dosage used preferentially blocks TTCC currents over other VGCC subtypes (Todorovic and Lingle, 1998; Fox et al., 1987).

    • Synthetic Aβ oligomers (Aβ<inf>1-42</inf> globulomer) modulate presynaptic calcium currents: Prevention of Aβ-induced synaptic deficits by calcium channel blockers

      2013, European Journal of Pharmacology
      Citation Excerpt :

      For therapeutic purposes it is now state-of-the-art to develop low molecular weight compounds with state-dependent properties (Mezler et al., 2012b), which preferentially target the inactivated state of the channel. Those molecules are believed to exhibit fewer side effects by preferentially targeting pathologically overactive synapses (Jimenez et al., 2000). Thus, we also tested whether oligomeric Aβ-induced deficits could also be reversed with state-dependent calcium channel blockers derived from an active drug development program.

    • State-dependent properties of a new T-type calcium channel blocker enhance Ca<inf>V</inf>3.2 selectivity and support analgesic effects

      2013, Pain
      Citation Excerpt :

      The concept of state-dependent effect of a drug on ion channels has been described for a long time for sodium and calcium channels [17]. This is the case for mibefradil that has good affinity for T-type channels but affects a number of other targets [4,21,29]. Interestingly the binding of tritiated-TTA-A1, a close structural analog of TTA-A2 [23], to membranes prepared from cells expressing CaV3.3 can be displaced by mibefradil, suggesting common structural determinants for their binding pocket [46].

    View all citing articles on Scopus
    View full text